EQRx Launches With $200M Series A For Cheaper Drugs

EQRx, a biotech company aimed at creating less expensive medicine, has raised a massive $200 million Series A.

Its goal is to re-engineer the process by which drugs are made by creating “novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems.”

EQRx says its medicines and therapies will be available “at dramatically lower prices.” Chairman and CEO Alexis Borisy said technological advances have made treating certain diseases easier than in years past.

Dr. Krishna Yeshwant, a general partner at GV, said EQRx’s business model will “deliver a sustainable approach for creating, reinvesting in and rewarding therapeutics innovation, while ensuring these new medicines are broadly accessible to people and healthcare systems through dramatically lower pricing.”

Full Article